FDA Follow-On Biologics Letter Creates Hurdle For Obama Administration
Executive Summary
A letter from FDA to the House Energy & Commerce Committee could delay any plans the incoming Obama Administration may have in moving forward with an abbreviated pathway to approve follow-on biologics
You may also be interested in...
Follow-On Biologics Theatre: Next Act Is FDA
A House subcommittee hearing on FTC’s report on FOB competition includes yelling, a “challenge” to take an FOB product – and a promise from Chairman Pallone for more of the same.
Frank Torti’s Next 100 Days: Active, Not Just Acting FDA Commissioner
Frank Torti might not be in charge of FDA for very long, but he seems determined to make his time count
Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing
Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug